Ovid Therapeutics (OVID) Competitors

$2.80 -0.01 (-0.18%)

As of 03:29 PM Eastern

OVID vs. DMRA, PGEN, HROW, ATAI, and IMTX

Should you buy Ovid Therapeutics stock or one of its competitors? MarketBeat compares Ovid Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ovid Therapeutics include Damora Therapeutics, Inc. Common Stock (DMRA), Precigen (PGEN), Harrow (HROW), Atai Beckley (ATAI), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Ovid Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Ovid Therapeutics (NASDAQ:OVID) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -31.36% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-31.36%	-24.81%
Damora Therapeutics, Inc. Common Stock	N/A	-147.05%	-247.50%

In the previous week, Ovid Therapeutics had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Ovid Therapeutics and 4 mentions for Damora Therapeutics, Inc. Common Stock. Ovid Therapeutics' average media sentiment score of 1.10 beat Damora Therapeutics, Inc. Common Stock's score of 0.07 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Ovid Therapeutics presently has a consensus price target of $5.13, suggesting a potential upside of 83.36%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $43.40, suggesting a potential upside of 80.76%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ovid Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.12M	51.75	-$17.41M	-$0.29	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$12.10	N/A

Summary

Ovid Therapeutics beats Damora Therapeutics, Inc. Common Stock on 12 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Precigen?

Ovid Therapeutics (NASDAQ:OVID) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Ovid Therapeutics has a net margin of -240.11% compared to Precigen's net margin of -2,588.21%. Precigen's return on equity of 2,317.96% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-31.36%	-24.81%
Precigen	-2,588.21%	2,317.96%	49.65%

In the previous week, Precigen had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 11 mentions for Precigen and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.10 beat Precigen's score of 0.65 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has higher earnings, but lower revenue than Precigen. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.12M	51.75	-$17.41M	-$0.29	N/A
Precigen	$9.68M	172.36	-$250.64M	-$1.34	N/A

Ovid Therapeutics presently has a consensus price target of $5.13, suggesting a potential upside of 83.36%. Precigen has a consensus price target of $11.00, suggesting a potential upside of 135.04%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Precigen	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Precigen has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Precigen beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Harrow has a net margin of -5.57% compared to Ovid Therapeutics' net margin of -240.11%. Harrow's return on equity of 19.59% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Ovid Therapeutics	-240.11%	-31.36%	-24.81%

In the previous week, Harrow had 9 more articles in the media than Ovid Therapeutics. MarketBeat recorded 14 mentions for Harrow and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.10 beat Harrow's score of -0.10 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has higher revenue and earnings than Ovid Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	4.32	-$5.14M	-$0.41	N/A
Ovid Therapeutics	$7.12M	51.75	-$17.41M	-$0.29	N/A

Harrow currently has a consensus price target of $69.43, indicating a potential upside of 123.19%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 83.36%. Given Harrow's higher possible upside, equities research analysts plainly believe Harrow is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Harrow has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

72.8% of Harrow shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 13.1% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Harrow beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Atai Beckley had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for Atai Beckley and 5 mentions for Ovid Therapeutics. Atai Beckley's average media sentiment score of 1.25 beat Ovid Therapeutics' score of 1.10 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a net margin of -240.11% compared to Atai Beckley's net margin of -19,019.44%. Ovid Therapeutics' return on equity of -31.36% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Ovid Therapeutics	-240.11%	-31.36%	-24.81%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 26.8% of Atai Beckley shares are held by company insiders. Comparatively, 13.1% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ovid Therapeutics has higher revenue and earnings than Atai Beckley. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	368.27	-$660.05M	-$2.30	N/A
Ovid Therapeutics	$7.12M	51.75	-$17.41M	-$0.29	N/A

Atai Beckley has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Atai Beckley currently has a consensus price target of $14.63, indicating a potential upside of 256.27%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 83.36%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Atai Beckley beats Ovid Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Immatics and Immatics both had 5 articles in the media. Ovid Therapeutics' average media sentiment score of 1.10 beat Immatics' score of -0.35 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a net margin of -240.11% compared to Immatics' net margin of -572.35%. Ovid Therapeutics' return on equity of -31.36% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.65%	-39.46%
Ovid Therapeutics	-240.11%	-31.36%	-24.81%

64.4% of Immatics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 13.1% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ovid Therapeutics has lower revenue, but higher earnings than Immatics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	27.23	-$222.26M	-$1.84	N/A
Ovid Therapeutics	$7.12M	51.75	-$17.41M	-$0.29	N/A

Immatics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Immatics currently has a consensus price target of $19.00, indicating a potential upside of 71.33%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 83.36%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Ovid Therapeutics beats Immatics on 12 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$368.59M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-9.64	18.77	20.85	25.56
Price / Sales	51.75	263.59	543.57	72.25
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.80	6.77	9.87	6.72
Net Income	-$17.41M	$24.11M	$3.55B	$333.62M
7 Day Performance	2.38%	0.17%	-0.23%	0.35%
1 Month Performance	-5.57%	0.98%	1.47%	4.00%
1 Year Performance	847.78%	78.11%	41.05%	36.32%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.9582 of 5 stars	$2.80 -0.2%	$5.13 +83.4%	+879.0%	$368.59M	$7.12M	N/A	60	Positive News Earnings Report Analyst Forecast
DMRA Damora Therapeutics, Inc. Common Stock	2.384 of 5 stars	$25.53 -1.5%	$43.40 +70.0%	+765.9%	$1.54B	N/A	N/A	40	Earnings Report
PGEN Precigen	3.7426 of 5 stars	$4.29 +3.5%	$9.50 +121.7%	+207.4%	$1.53B	$9.68M	N/A	190	News Coverage Earnings Report Analyst Forecast Gap Up
HROW Harrow	3.2627 of 5 stars	$40.73 +1.3%	$69.86 +71.5%	+13.6%	$1.52B	$272.30M	N/A	180	News Coverage Earnings Report Analyst Forecast
ATAI Atai Beckley	3.9637 of 5 stars	$4.13 -1.8%	$14.63 +254.5%	+200.7%	$1.51B	$4.09M	N/A	80	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. DMRA, PGEN, HROW, ATAI, and IMTX

How does Ovid Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Ovid Therapeutics compare to Precigen?

Summary

How does Ovid Therapeutics compare to Harrow?

Summary

How does Ovid Therapeutics compare to Atai Beckley?

Summary

How does Ovid Therapeutics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. DMRA, PGEN, HROW, ATAI, and IMTX

How does Ovid Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Is OVID or DMRA more profitable?

Does the media refer more to OVID or DMRA?

Which has more risk & volatility, OVID or DMRA?

Do analysts rate OVID or DMRA?

Do institutionals & insiders hold more shares of OVID or DMRA?

Which has stronger valuation & earnings, OVID or DMRA?

Summary

How does Ovid Therapeutics compare to Precigen?

Is OVID or PGEN more profitable?

Does the media refer more to OVID or PGEN?

Which has stronger valuation & earnings, OVID or PGEN?

Do analysts rate OVID or PGEN?

Which has more risk & volatility, OVID or PGEN?

Do institutionals & insiders hold more shares of OVID or PGEN?

Summary

How does Ovid Therapeutics compare to Harrow?

Is HROW or OVID more profitable?

Does the media favor HROW or OVID?

Which has preferable valuation & earnings, HROW or OVID?

Do analysts prefer HROW or OVID?

Which has more volatility & risk, HROW or OVID?

Do insiders and institutionals hold more shares of HROW or OVID?

Summary

How does Ovid Therapeutics compare to Atai Beckley?

Does the media favor ATAI or OVID?

Is ATAI or OVID more profitable?

Do institutionals and insiders hold more shares of ATAI or OVID?

Which has better earnings & valuation, ATAI or OVID?

Which has more volatility and risk, ATAI or OVID?

Do analysts prefer ATAI or OVID?

Summary

How does Ovid Therapeutics compare to Immatics?

Does the media favor IMTX or OVID?

Is IMTX or OVID more profitable?

Do institutionals and insiders hold more shares of IMTX or OVID?

Which has better earnings & valuation, IMTX or OVID?

Which has more volatility and risk, IMTX or OVID?

Do analysts prefer IMTX or OVID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools